Yichang SanXia Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Renfu Pharmaceutical Group, is a comprehensive biopharmaceutical enterprise that researches and produces antibiotic APIs, amino acid series large-capacity injections, and animal drug preparations, and is a national high-tech enterprise. In recent years, the company has successively won the titles of "Hubei Province Pharmaceutical Industry API Export Excellent Enterprise", "Hubei Province Top 10 Export Enterprises Earning Foreign Exchange", "Hubei Province Pillar Industry Segment Invisible Champion Science and Technology Little Giant" and other titles, and the registered trademark of "Three Gorges Brand" has been recognized as a well-known trademark in Yichang City.
The company currently covers an area of 300,000 square meters, with four industrial bases: Yichang High-tech Zone Industrial Park, Dianjun Industrial Park, Xiaoting Subsidiary and the newly built Yuan'an Branch, and is a global large-scale supplier of neomycin sulfate APIs, with subdivided product lines covering veterinary neomycin sulfate, flavamectin sulfate, prescription human neomycin sulfate, etc. The product has passed the US FDA and EU CEP certification, and neomycin sulfate has won the title of "Single Champion Product in Manufacturing" awarded by the Ministry of Industry and Information Technology of China, with a global market share of more than 70%. The company is also one of the earliest manufacturers of amino acid large-capacity injections in China, and the "Three Gorges brand" series of amino acid large-capacity injections have been recognized as "famous brand products" and "high-quality products" in Hubei Province.
The company has more than 700 employees, accounting for 30% of all kinds of professional and technical personnel, has established a professional R&D team with complete facilities, established an industry-university-research platform with a number of colleges and universities, and has done a lot of research work in improving the level of production technology and new product development, and now has 31 authorized patents and 30 scientific and technological achievements. Based on the advantages of neomycin sulfate technology and resources, the company optimizes the product structure, focuses on the high-end market, and realizes strategic transformation and upgrading. The company passed the new version of veterinary drug GMP certification in 2020, and has also made breakthroughs in the research and development and manufacturing of pet drugs, and there are 43 varieties of pet drugs approved for development and approval at this stage, and the product categories involve antibacterial drugs, antiparasitic drugs, antipyretic and analgesic drugs, non-steroidal anti-inflammatory drugs, gastrointestinal drugs, anesthetics, etc.
In the next 3-5 years, the company will focus on the implementation of the API system with neomycin as the core, the veterinary drug preparation system with neomycin-related preparations as the core, the human drug preparation system with amino acid infusion as the core, and the pet drug preparation system with new pet drugs as the core, and ensure the international leading position of neomycin sulfate APIs, become a professional manufacturer of animal drugs, continue to maintain the traditional position in the field of amino acid infusion, and make greater contributions to local development.
No. 8 Ziyang Road, Dian Military District, Yichang City, Hubei Province
No. 35, Dalian Road, Yichang High-tech Zone (headquarters office address)
